{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:16:01Z","timestamp":1753877761069,"version":"3.41.2"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Small cell lung cancer (SCLC) is known for its high proliferative rate and poor prognosis. Although Delta\u2010like ligand 3 (DLL3) is specifically expressed on the surface of SCLC, the association of DLL3 with prognosis in SCLC remains uncertain. Hence, we aimed to evaluate prognostic role of DLL3 in extensive stage of SCLC treated with first\u2010line chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A total of 54 patients with extensive stage of SCLC (ES\u2010SCLC) who were treated with first\u2010line chemotherapy were included for our analysis. In addition, tissue specimen should be available for immuno\u2010histochemical staining for DLL3, and their clinico\u2010pathologic data, including progression\u2010free survival (PFS) and overall survival (OS), were obtained. DLL3 expression and the percentage of tumor cells with DLL3 positive among total cancer cells were analyzed microscopically and DLL3 high and DLL3 low were defined as the percentage of DLL3 positive tumor cells versus total cancer cells \u2267\u200975% and &lt;\u200975%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>DLL3 expression was not associated with any of the clinico\u2010pathological characteristics such as age at diagnosis, sex, response to first\u2010line chemotherapy, second\u2010line chemotherapy (Yes or No), and number of metastatic sites. However, response to first\u2010line chemotherapy and number of metastatic sites were correlated to PFS, while DLL3 expression and number of metastatic sites were correlated to OS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>DLL3 was highly expressed in SCLC, and not associated with any clinico\u2010pathological characteristics. In survival outcome, DLL3 was correlated with worse OS, which suggests the prognostic role of DLL3 in ES\u2010SCLC.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.15522","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T11:04:48Z","timestamp":1735297488000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of <scp>DLL3<\/scp> Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First\u2010Line Chemotherapy"],"prefix":"10.1111","volume":"16","author":[{"given":"Hohyung","family":"Nam","sequence":"first","affiliation":[{"name":"Department of Hematology, Seoul St. Mary's Hospital, College of Medicine Catholic University  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon\u2010Hee","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Pathology Yonsei University Wonju College of Medicine  Wonju Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jii Bum","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center Yonsei University College of Medicine  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Hyun","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology, Division of Internal Medicine, Wonju Severance Christian Hospital Yonsei University Wonju College of Medicine  Wonju Korea"},{"name":"Center of Evidence\u2010Based Medicine, Institute of Convergence Science Yonsei University  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7258-2263","authenticated-orcid":false,"given":"Seungtaek","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology, Division of Internal Medicine, Wonju Severance Christian Hospital Yonsei University Wonju College of Medicine  Wonju Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.12.006"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2114"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac9459"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13997"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0745-2"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30565-4"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.009"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02823"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0196"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.07.026"},{"key":"e_1_2_9_15_1","first-page":"2254","article-title":"Prognostic Value of Delta\u2010Like Protein 3 Combined With Thyroid Transcription Factor\u20101 in Small\u2010Cell Lung Cancer","volume":"18","author":"Yan L. X.","year":"2019","journal-title":"Oncology Letters"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.018"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.07.016"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-020-02004-5"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S216362"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0497-OA"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0676"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.15522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:49:03Z","timestamp":1738277343000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.15522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/1759-7714.15522"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.15522","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"type":"print","value":"1759-7706"},{"type":"electronic","value":"1759-7714"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"2024-07-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15522"}}